Nanjing Leads Biolabs completes enrollment in Phase II Opamtistomig trial for advanced biliary tract cancer

PUBT · 2d ago
Nanjing Leads Biolabs completes enrollment in Phase II Opamtistomig trial for advanced biliary tract cancer
  • Nanjing Leads Biolabs completed full enrollment of 70 patients in a Phase II study of LBL-024 for first-line advanced biliary tract cancer.
  • The trial moved into an expansion phase in April 2026 on favorable safety and early efficacy signals, with no new safety concerns flagged.
  • Results have not yet been presented; data are slated for release at the ESMO Annual Meeting in Madrid on Oct. 23-27, 2026.
  • The update positions LBL-024 as a potential next-generation immunotherapy option in a setting where current chemo-immunotherapy regimens deliver limited benefit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12262151), on July 30, 2026, and is solely responsible for the information contained therein.